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DEPRESSIVE DISORDERS ERODE QUALITY OF LIFE,productivity in the workplace, and fulfillmentof social and famil ia l roles . In today ’sknowledge- and service-driven economies, the
population’s mental capital (ie, cognitive, emotional, and
social skills resources required for role functioning)
becomes both more valuable and more vulnerable to the
effects of depression. Depressive disorders, severe mental
illnesses that should not be confused with normal mood
variations, are part of a vicious circle of poverty, discrimi-
nation, and poor mental health in middle- and low-
income countries.1 These realities also have major eco-
nomic ramifications: treatment costs of depression are
soaring but are only a fragment of the costs of reduced
productivity due to depression.2
More than half of those with depression develop a
recurrent or chronic disorder after a first depressive epi-
sode and are likely to spend more than 20% of their life-
time in a depressed condition. With a 12-month preva-
lence rate of more than 5% in most high-, middle-, and
low-income countries and its occurrence at almost any
age,3 depression generates substantial loss of quality of
life and personal morbidity and despair. But it also leads
to considerable additional damage through biological
sequelae and maladaptive illness behaviors, thus increas-
ing risk of cardiovascular disease, dementing illnesses,
and early death while amplifying disability, complica-
tions, and health services use in those with coexisting
chronic illnesses. Depression ranks third among disor-
ders responsible for global disease burden, with all the
concomitant economic costs to society, and will rank first
in high-income countries by 2030.4
Prevention of Depression: New Opportunities
Even if it were possible to provide evidence-based treat-
ment to all persons affected by a depressive disorder, the
effect on averting years lived with disability would be
limited because of the steady influx of new patients and
the limited efficacy of currently available treatments.5
Prevention may offer new possibilities to reduce the dis-
ease burden of depressive disorders. A report of the Insti-
tute of Medicine defined prevention as any intervention
aimed at preventing the onset of new cases of mental dis-
orders in people who do not yet meet criteria for such a
disorder.6 Prevention may be directed toward the whole
population (universal prevention), high-risk groups (se-
lective prevention), or those with subsyndromal symp-
toms (indicated prevention). More than 30 randomized
trials have demonstrated that preventive interventions
can reduce the incidence of new episodes of major
depressive disorder by about 25% and by as much as 50%
when preventive interventions are offered in stepped-care
format.7 Methods with proven effectiveness involve edu-
cational, psychotherapeutic, pharmacological, lifestyle,
and nutritional interventions.
The Economic Case for Depression Prevention
Cost-effectiveness ratios for preventive interventions are at-
tractive,2 with numbers needed to treat to prevent 1 case of
depression ranging between 8 and 10,7 an effect size com-
paring favorably with established preventive interventions
for other conditions (eg, number needed to treat=21 using
statins for 5 years to prevent anothermyocardial infarction).8
In addition, the financial costs of averting 1 year lived with
depression-related disability is below the current ceiling of
$30 000 to $50 000 generally accepted by policy makers as
cost-effective.
Research Priorities for Prevention of Depression
The positive findings of selective and indicated preven-
tion trials are of great public health significance, but full
use of evidence-based depression prevention strategies
has yet to be realized. This gap between what is known
and implementation of these strategies requires attention,
action, and the strengthening of research and dissemina-
tion efforts. The Global Consortium for Depression Pre-
vention, which convened in Utrecht, the Netherlands, in
September 2011, compared progress made in depression
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prevention with that in cardiovascular disease. Cardio-
vascular morbidity and mortality have declined, reflect-
ing combined effects of improvements in treatment and
prevention. In comparison, the consortium advocates
integrating prevention of depression with improvements
in diagnosis and treatment with the aim of decreasing the
global illness and economic burden of depression.
Research priorities identified by the consortium are listed
in the BOX.
Conclusion
Depression prevention research and practice have pro-
gressed from a pioneering stage to one in which evidence-
supported and cost-effective interventions can be dissemi-
nated on a larger scale and prevention can help to lessen
the global disease burden.
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Box. Research Priorities for Prevention of Depression
• Identify ways to improve access to effective strategies by
those at risk. For example, preventing intergenerational
transmission of depression requires effective, acceptable,
and scalable interventions for families and in the school en-
vironment,whilepreventingdepression inolderpeoplewith
physical illness requires embedding preventive research in
health care settings and social services. To reduce the ef-
fect of depression on productivity losses, including prema-
ture retirement, prevention programs suitable for thework
environmentneeddevelopment.Theuseofnewmedia, such
as e-mental health and smart phone technologies, and the
use of lay health counselors may boost dissemination, es-
pecially in low- and middle-income countries.
• Study howdepression in one person has cascading or con-
tagion effects on others close to him/her in terms of their
productivity, health, and well-being.
• Because preventive interventions are likely to have mul-
tiple effects beyonddepressionor evenmental illness in gen-
eral, measure multiple outcomes beyond health, includ-
ing economic, educational, and social role functioning.
• Focus on risk factors for developing mental disorders in
general (eg, sleep disturbance, social isolation, child abuse
and neglect, and disabilities associated with medical and
neurological disease). In the prodromal or at-risk phases,
it is not yet clear which disorder will develop. Such an
approach will extend the focus of prevention and stimu-
late collaborations among different subfields of preven-
tion of mental disorders.
• Develop interventions based on causal mechanisms un-
derlying risk: in addition to social stressors, address psy-
chological and biological markers of risk (neuroticism,
sleep, proinflammatory cytokines, etc) to achieve more
targeted and rational interventions.
• Incorporate economic analysis of costs and benefits. De-
velopment of stepped-care programs will facilitate
approaching larger numbers of people at risk with self-
help, e-health, or other relatively inexpensive and easy-
to-disseminate nonconsumable materials, restricting the
use of more intensive interventions to those who do not
respond favorably.
• Universal, selective, and indicated preventionmay be used
in concert. Currently, it remains unknown what is the
most effective strategy to reduce the burden of depres-
sion; targeted research is needed to determine which type
of prevention is associated with the best value for money.
• Develop strategies for producingmore enduring preven-
tive effects. Although evidence exists for the efficacy of
interventions for reducing the onset of depressive epi-
sodes, additional research is needed on how tomake these
effects endure. The use of booster sessions and Internet
technologies should be explored.
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